XLO Stock Analysis: Buy, Sell, or Hold?
XLO - Xilio Therapeutics, Inc. Common Stock
$8.34
0.03 (0.36%)
▲
5d:
+8.59%
30d:
-5.33%
90d:
+8.88%
BUY
MODERATE Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Get Alerted When XLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: XLO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: XLO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: XLO is currently trading at $8.34, which is considered slightly high relative to its 30-day fair value range of $7.84 to $8.45. From a valuation perspective, the stock is trading at a discount (Forward PE: -3.2) compared to its historical average (23.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XLO is in a strong uptrend. Immediate support is located at $7.53, while resistance sits at $8.75.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.00 (+140.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XLO is in a strong uptrend. Immediate support is located at $7.53, while resistance sits at $8.75.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.00 (+140.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.84 -
$8.45
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 140.7% below Wall St target ($20.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$7.84 -
$8.45
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$7.53
Resistance Level
$8.75
Current Trend
Strong Uptrend
Technical data as of
Jun 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.21
Wall Street Target
$20.00
(+140.7%)
Revenue Growth (YoY)
331.7%
Profit Margin
-58.5%
PE vs Historical
-3.2 vs 23.0
CHEAP
Share & Embed Analysis
Last updated: June 15, 2026 4:12 PM ET
Data refreshes hourly during market hours. Next update: 5:12 PM
Data refreshes hourly during market hours. Next update: 5:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 62 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 53 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |